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Staphylococcus  aureus  is a  highly  versatile  gram  positive  bacterium  that  is  resident  as  an  asymptomatic
colonizer  on  the  skin  and  in  the nasopharynx  of  approximately  30%  of  individuals.  Nasopharyngeal  col-
onization  is  a risk  for acquiring  S.  aureus  infections,  which  can  cause  a range  of clinical  symptoms  that
are  commonly  associated  with  skin  and  soft-tissue  infections.  The  emergence  of  S.  aureus  strains  that
are highly  resistant  to  antimicrobials  has  recently  become  a major  public  health  concern.  In  low-income
countries  the  incidence  of  S. aureus  disease  is  highest  in neonates  and  children  up to  one  year  of  age  and
mortality  rates  are estimated  to be up to 50%.  In  the  United  States,  S. aureus  infection  accounts  for  approx-
imately  300,000  hospitalizations  per  year.  A vaccine  against  multi-drug  resistant  S. aureus,  therefore,  is
urgently needed.  Two  vaccine  candidates  have  previously  been  evaluated  in  late-stage  clinical  trials  but
have  not  demonstrated  efﬁcacy.  At present,  one  vaccine  candidate  and  two  monoclonal  antibody  are
undergoing  clinical  evaluation  in  target  groups  at high  risk  for S. aureus  infection.  This  review  provides
an  overview  of  current  vaccine  development  efforts  and  presents  the  major  technical  and regulatory
challenges  to developing  a licensed  S.  aureus  vaccine.
©  2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC. About the disease and pathogen
Staphylococcus aureus is a bacterium that is both an asymp-
omatic colonizer and frequent cause of disease in humans [1].
t is a highly versatile pathogen that causes a range of clinical
anifestations of varying severity, and is the most commonly iso-
ated pathogen in the setting of skin and soft-tissue infections,
eptic arthritis, pneumonia, endovascular infections, osteomyeli-
is, foreign-body associated infections, septicemia and toxic shock
yndrome [2]. S. aureus infections strike people of all ages and
ackgrounds, but are most severe in young children, the elderly,
he immunosuppressed and other individuals with major co-
orbidities [3,4]. The incidence of S. aureus infection in low income
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countries is highest in neonates and children up to one year of age
with mortality rates of up to 50% [5], in contrast to high income
countries where the disease appears to increase with age, or is most
prevalent at the extremes of the age spectrum. However, there have
been very few epidemiological studies in low and middle income
countries, and it is likely that there is an under-reporting of S.
aureus-associated disease generally, and particularly in the elderly
in these settings [6,7].
S. aureus is known to be highly adaptable, and in recent
history has shown a remarkable epidemiologic transition. Since
1959, when methicillin was  ﬁrst introduced, strains of methicillin-
resistant S. aureus (MRSA) have been documented at a rapid and
increasing rate. Hospital-associated MRSA (HA-MRSA) clones are
now recognized to be the leading cause of nosocomial infections in
low-, middle-, and high-income countries [5,8,9]. The emergence
of community-associated MRSA (CA-MRSA) in the past several
decades has also become a point of concern, as virulent strains
of CA-MRSA are fast-spreading and can affect seemingly healthy
individuals [10]. Vancomycin is currently the ﬁrst-line treatment
for severe CA-MRSA and HA-MRSA infections, however strains
with reduced susceptibility to this antimicrobial (vancomycin-
intermediate S. aureus (VISA) and vancomycin resistant S. aureus
(VRSA)) have been reported with increasing frequency [11]. Since
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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asal carriage is a well-deﬁned risk factor for infection, decolonisa-
ion protocols have had some moderate success in reducing the
ncidence of infection in speciﬁc hospitalized groups. However,
learance is not consistent or long-lived, and this strategy is not
pplicable to community settings. Efforts to prevent MRSA infec-
ion in high-income countries are well-resourced, but risk factors
nd infection are poorly monitored in low- and middle-income
ettings, where in some cases over-the-counter antibiotics are
vailable and frequently self-administered [12]. MRSA’s status as
 global public health threat will only be exacerbated by inappro-
riate anti-microbial use and will further accelerate the spread of
A-MRSA and other resistant microorganisms.
S. aureus,  which is constitutes the normal ﬂora in up to 30%
f individuals (either persistently or intermittently), is typically
pread via close contact from carriers to non-carriers. Transmis-
ion has been found to be most efﬁcient within healthcare and
thletic facilities [2,13]. In high income countries, target groups for
otential S. aureus vaccination would be at-risk healthcare work-
rs, the elderly ≥65 years, and the immunocompromised, as well
s patients with recurrent invasive staphylococcal infection [3,14].
he global burden and spread of S. aureus infection is currently
nknown and more data from low- and middle-income countries
re needed, but in the US alone, S. aureus infection is reported as a
ischarge diagnosis for around 300,000 hospital stays per year. S.
ureus infection is also associated with a ﬁve-fold increased risk
f in-hospital death and three-fold higher cost of hospital stay
ompared to inpatients without infection [15]. A US study in 2003
stimated that S. aureus infections accounted for $14.5 billion in all
npatient hospital stays and $12.3 billion for surgical stays [16].
. Overview of current efforts
. Either vaccines currently available and their limitations or bio-
logical feasibility for vaccine development
Prior S. aureus infection does not provide protection against
subsequent infection, but infections among carriers are less
severe, suggesting that some form of immunity does develop
during prolonged colonization. Although all adults have pre-
existing binding antibodies to S. aureus antigens, including
capsule and clumping factor A (ClfA), these do not typically
include functional antibodies that have opsonophagocytic or
neutralizing properties, and therefore do not provide protection
against infection.
There is precedence for the development of safe and effective
bacterial vaccines that target single antigens or toxins, partic-
ularly capsular polysaccharides. The most prominent examples
are the tetanus toxoid and pneumococcal conjugate vaccines.
Application of these technologies to S. aureus is complicated
by the bacterium’s complex mechanisms of pathogenesis. S.
aureus can comprise the normal human ﬂora and, as such, has
evolved a number of strategies to colonize and evade the host
immunity, including polymorphic expression of surface anti-
gens and release of multiple redundant virulence factors [17,18].
These include iron acquisition factors such as IsdB, manganese
uptake receptors such as MntABC, ﬁbronectin binding proteins
(ClfA, ClfB), polysaccharide capsule molecules (CP5 and CP8)
and toxic shock syndrome toxin (TSST). To date, vaccine can-
didates have targeted individual cell surface components, such
as the polysaccharide capsule, extracellular polysaccharides or
cell wall associated proteins that aid attachment, invasion or
act as a receptor (e.g., hemoglobin for iron utilization). Although
multiple vaccine candidates have shown promise through pre-
clinical development in a range of animal models, those that have
reached late stage clinical testing have failed to demonstrate
efﬁcacy in human trials [19,29].34 (2016) 2962–2966 2963
B. General approaches to vaccine development for this disease for
low and middle income country markets
S. aureus has not been viewed as a high-priority pathogen in
low-income countries. However, based on the limited data avail-
able, the incidence and mortality from multidrug-resistant S.
aureus in these regions is likely signiﬁcant, To date, only two
vaccines have completed human efﬁcacy, and neither have con-
templated target populations or indications that are prevalent
in low- and middle-income countries [20]. StaphVAX is a biva-
lent polysaccharide- and protein-conjugated vaccine, directed
against S. aureus capsular polysaccharide types 5 and 8 (CP5 and
CP8), which are associated with approximately 80% of S. aureus
clinical infections. The candidate was  evaluated in two  phase
III studies to prevent bacteremia in end-stage renal dialysis
patients in the 3–54 weeks following immunization. In the ﬁrst
40 weeks, bacteremia was reduced by 57% but efﬁcacy dropped
to 26% by week 54 [21]. A conﬁrmatory Phase III study involving
3600 heamodialysis patients who  were evaluated for bacteremia
showed no difference between vaccinated individuals and the
placebo controls. The functional antibody titers induced by the
vaccine in this second follow-up phase III study have not yet been
made publicly available. Currently, then, the main reason for the
second trial’s failure is being attributed to manufacturing incon-
sistencies between different vaccine lots used for the two  studies
[22]. Development of the candidate has been discontinued.
Another candidate, V710, elicits immunity against the cell-
wall anchored iron scavenger protein IsdB, and was evaluated
in a Phase III randomized controlled trial in approximately
8000 adults scheduled for cardiac surgery. This trial was  termi-
nated when an interim analysis showed a statistically signiﬁcant
increase in mortality rate due to S. aureus infection and a signif-
icantly higher rate of other adverse events [23].
Passive immunization strategies utilizing both polyclonal and
monoclonal antibodies (mAbs) have been targeted for those who
are immunocompromised and cannot mount an independent,
robust immune response and for those at immediate risk of
infection and do not have time to for an active immunization to
take effect. Five antibody candidates have been developed and
evaluated in late stage clinical studies; none have demonstrated
efﬁcacy [24].
The focus has been on development of a prophylactic product
that will protect against life-threatening S. aureus infections, but
it is hoped that such a vaccine would also protect against all
S. aureus infections including more commonly encountered skin
and soft tissue infections. To date, however, no product has been
shown to protect against any tested outcome.
3. Technical and regulatory assessment
Active and passive immunization approaches have been based
on increasing the concentration of opsonic antibodies to single
surface antigens, and all have failed to demonstrate protection.
Antigenic variation and the multiple invasion and colonization
mechanisms of S. aureus, absence of representative preclinical
models and lack of immune correlates or surrogates of pro-
tection all present signiﬁcant obstacles to the rational design,
development and evaluation of potentially successful vaccine
candidates.
Leaders in the ﬁeld have been speculating about the future
directions for S. aureus vaccine development, particularly in the
aftermath of the failed efﬁcacy trials [25–28]. First and foremost,
a multi-antigen approach that targets both cell surface compo-
nents and secreted virulence factors, and potentially responses
against the disease causing toxins, have been hypothesized as
essential to the success of a vaccine. Because S. aureus causes
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 broad range of diseases, preclinical testing should involve the
se of multiple models that approximate the different diseases
hat the pathogen causes in humans. Many candidates have been
valuated in murine models, due to convenience and low cost,
nd have demonstrated proof-of-concept in terms of preclinical
rotection through the elicitation of opsonic antibodies. How-
ver, these data have not translated into human efﬁcacy [19,29].
n addition to developing a number of representative preclinical
odels, it is also important to evaluate protection against diverse
. aureus clinical isolates, and to assess development of in vitro
ssays that measure functional responses through the induction
f both humoral and T-cell mediated responses, particularly toxin
eutralization, opsonophagocytic killing by neutrophils, and IL-17
ecretion.
The optimal population for clinical proof-of-concept or efﬁcacy
tudies is challenging to identify. Generally speaking, the more
mmune compromised the patient, the greater the severity of S.
ureus infection. However, these individuals are less likely to mount
n effective immune response after vaccination. Patient groups
ho are generally healthy but elect to undergo surgery or some
ther invasive procedure are typical target populations for efﬁ-
acy studies, as vaccination can be administered prior to a known
eriod of increased risk (approximately 90 days) and be compared
o a placebo. Regardless of the population in which vaccine proof-
f-concept is demonstrated, an efﬁcacious vaccine will ultimately
e targeted to patients at who are already at high risk of infec-
ion and are not in good health at baseline (immunocompromised
r with co-morbidities). Prospective studies across a number of
able 1
evelopment status of Current vaccine candidates.
Candidate
name/Identiﬁer
Developer Vaccine approach Pre-
Active prophylactic vaccines
PF-06290510/SA4Ag Phizer ClfA/MntC/CP5/CP8
conjugated to CRM197
GSK2392103A GSK CP5/CP8/TT/AT/ClfA
plus AS03B
NDV3 NovaDigm
Therapeutics
rAls3p-N (C.albicans
surface protein that
cross reacts with S.
aureus)  plus Alum
Glycosylated CP5, CP8,
and HlaH35L
GSK (Glycovaxyn) 
SA75 Vaccine Research
International
Whole cell vaccine 
4C-Staph Novartis FhiD2, EsxAB, Hla,
Sur-2
SAG Pan Chai University S. aureus ghosts 
various IBT/NIAID Multi-valent
attenuated toxoid
Passive prophylactic immunization
MEDI4893 Medimmune mAb  binding to S.
aureus toxin
AR-301 Aridis mAb  34 (2016) 2962–2966
elective surgery populations that deﬁne the risk, characteristics of
surgical procedures, co-morbidities and infections rates are needed
to accurately identify the optimal population in which to test S.
aureus vaccines, as well as to plan how such a vaccine may  be most
impactful.
Recent analysis of the data from V710 vaccine recipients indi-
cates that the combination of low pre-vaccination IL-2 levels,
vaccination with V710, and post-operative S. aureus infection
were associated with increased mortality following cardiothoracic
surgery [30]. Nine of ten V710 recipients with undetectable pre-
operative IL17a levels and postoperative S. aureus infections died.
Investigation into the pathophysiologic mechanism of this outcome
is ongoing.
A vaccine that offers sterilizing protection from S. aureus may
be an overly ambitious target, but would be ideal. The alternative
to a vaccine that protects against all clinical S. aureus syndromes
is to develop vaccines against each or a subset of speciﬁc clinical
manifestations, however this would be very costly, and certainly
challenging for use in low income countries. A more achievable
end point may  be reduction in the severity of infection, as this may
still have a very important impact on mortality.
S. aureus vaccines could also be considered a high priority within
the antimicrobial resistance (AMR) agenda together with, for exam-
ple, Group A Streptococcal, P. falciparum malaria and tuberculosis
vaccines. However, the AMR  research agenda has not yet fully
incorporated vaccine R&D perspectives. A discussion about incen-
tivizing vaccine development to address AMR  concerns is needed
at national and international policy levels.
clinical Phase I Phase II Status
X Safety and Efﬁcacy of SA4Ag Vaccine in Adults
Having Elective Posterior Instrumented
Lumbar Spinal Fusion Procedure (STRIVE):
NCT01827358
X SA4Ag Safety, Tolerability, and
Immunogenicity Study in Japanese Adults:
NCT02492958
X No longer under active development. A Study
to Evaluate the Safety, Reactogenicity and
Immunogenicity of GSK Biologicals’
Staphylococcal Investigational Vaccine in
Healthy Adults: NCT01160172 [34]
X Under development. Safety and
Immunogenicity Study of a Recombinant
Protein Vaccine (NDV-3) Against S. aureus and
Candida: NCT01273922. Clinical development
for Vulvovaginal candidiasis (VVC) ongoing:
NCT01926028
X [33]
X No longer under active development http://
www.vri.org.uk/PhaseITrial.pdf
X [35]
X [36]
X [37]
X Dose-ranging efﬁcacy and safety in
mechanically Ventilated Adults: NCT02296320
X Phase I/II Safety, Pharmacokinetics and Efﬁcacy
of KBSA301 in Severe Pneumonia (S. aureus) as
an adjunctive therapy to standard of care
antibiotics in hospital-acquired pneumonia
(HAP) and ventilator associated pneumonia
(VAP) patients: NCT01589185
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. Status of vaccine R&D activities
Following the failure of single antigen vaccine approaches,
ost development efforts are now focused on multiple anti-
en approaches. Pﬁzer’s SA4Ag candidate is currently the most
dvanced and is comprised of four antigens: the adhesion molecule
lfA, the manganese transporter MntC and anti-phagocytic cap-
ular polysaccharides 5 and 8 [31]. This combination is designed
o elicit broad humoral and cellular immune responses against
ultiple virulence mechanisms involved in the establishment and
aintenance of infection. Results from a phase I study in which
ealthy adults of ages 50–85 (n = 312) or 18–24 (n = 96) years
andomly received a one of three dosages of SA4Ag as a sin-
le intramuscular injection or placebo showed that the 50- to
5-year age stratum elicited robust immune responses to all com-
onent antigens, as well as functional responses as measured by
n opsonophagocytic activity assay. The rise in functional anti-
ody titers against S. aureus was maintained through at least 12
onths. A phase IIb placebo-controlled safety and efﬁcacy study
n adults undergoing elective spinal fusion surgery is underway
referred to as STRIVE: STaphylococcus aureus SuRgical Inpatient
accine Efﬁcacy). SA4Ag was granted Fast Track designation
y the U.S. Food and Drug Administration (FDA) in February
014.
Other multi-antigen preclinical candidates targeting conserved
apsular polysaccharide conjugates and/or protein antigens, some
ncluding toxins such as alpha toxin, TSST, and SEB are in devel-
pment (Table 1). In the face of past failures, current efforts are
lso focused on further characterizing the immunopathology and
mmunity of S. aureus infections to identify new antigenic tar-
ets, and developing more representative preclinical [32] models
n which opsonising and/or neutralizing immune responses are
easured.
Passive immunization with mAbs is an alternative strategy to
anage S. aureus infection in the context of increasing antimi-
robial resistance. Questions about affordability and access of
Ab interventions for low- and middle-income countries need
o be clariﬁed. As with previous vaccine candidates, clinical tri-
ls examining the efﬁcacy of human antibodies have failed to
eet their study end points and have been discontinued [19,29].
 new generation of mAbs is now undergoing clinical evalua-
ion. Aridis Pharmaceuticals’ candidate AR-301 (SalvecinTM) is a
ully human monoclonal IgG1 antibody targeting S. aureus alpha-
oxin that is undergoing evaluation as an adjunctive therapy to
tandard-of-care antibiotic treatement for hospital-acquired pneu-
onia (HAP) and ventilator associated pneumonia (VAP) [38].
edimmune’s MEDI4893 long half-life mAb  is also targeting the
lpha toxin, and is currently in a Phase 2 dose-ranging study to
valuate safety and efﬁcacy in mechanically ventilated adult sub-
ects [39].
. Likelihood for ﬁnancing
The relatively well-characterized incidence of S. aureus in high-
ncome countries and the market potential for a vaccine has meant
hat development, particularly through late-stage clinical testing,
as to date been advanced by pharmaceutical companies. Basic
esearch into S. aureus pathogenesis, development of improved
reclinical models and functional assays is being supported by gov-
rnment funding agencies such as the European Commission and
he National Institutes of Health. However, there are no efforts
o develop a vaccine against S. aureus infections in low- and
iddle-income countries as no market has yet been established
here.
[34 (2016) 2962–2966 2965
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